Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

NCT01344876 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoid Leukemia
Chronic Myeloid Leukemia

Interventions

DRUG: OPB-51602

Sponsor

Otsuka Pharmaceutical Co., Ltd.